I have use 3F4 anti-prion antibody but this antibody doesn't give a clear result. There is variable intensity of bands even when I loaded the same concentration of protein in each lane.
First question is: are you sure the 3F4 epitope was conserved in your PrPC species? Usually the 3F4 is a great anti-PrPC antibody, perhaps one of the most reliable and efficient...
Look at the paper of Oelschlegel A et al or Gretzschel A et al. http://www.ncbi.nlm.nih.gov/pubmed/17098989 or check for Groschup MH. there are a couple of paper's from that group that stained the prion protein with 3F4 antibody, both PrPC and Sc.
The PrP antigen sequence acting as an epitope of the 3F4
Furthermore, information was acquired from antibody
investigations aimed at blocking the transformation of PrPc
into PrPsc. The PrP antigen sequence acting as an epitope
of the 3F4 antibody, varies from 4 to12 amino acids,
depending on the animal species (Lund, Olsen, Tveit, &
Tranulis, 2007; Zou et al., 2010a), 3F4, a monoclonal antibody
(MAb), has been recognized as a reagent that greatly
facilitates research on PrP and prion diseases (Zou et al.,
2010a). The minimum sequence consists of the
109MKHM112 tetrapeptide common to human and hamster
PrP and the same sequence with different numbering
occurs in other species (Zou et al., 2010a). The same case
is applicable to the heptapeptide 106KTNMKHV115 for
bovine and elk PrP (Zou et al., 2010a) and
106KTNMKHM115 (Lund et al., 2007) for humans and
hamsters and 104KPKTNMKHMA113 with an Ω loop
structure. (Determination by X-ray (Kanyo, 1999).
These amino acid sequences are not sterically accessible in PrPc, but can be presented to 3F4 in PrPsc (Figure 7). The Lys106 residue is proved to be a critical residue as shown by the marked reduction of 3F4 binding observed after a deletion in the 12-mer PrP peptide 107 (Lund et al., 2007; Zou et al., 2010a). However,
3F4 remains the most important monoclonal antibody in
studies related to human prion disease, and it confirms that our miniprion_beta PrPsc 92–138 can easily enter the 3F4 epitope, allowing immunoreactivity with the minimum sequence 106KTNMK110 (humans) and 106KTNLK110 (mouse) (Lund et al., 2007). The epitope shown in Figure 7 is no longer accessible in nondenatured PrPsc, showing that PrP transconforms during
scrapie infection and adapts to epitope 3F4. A large
portion of the PrP molecules was subjected to proteolytic
processing, giving a positive reaction with 3F4 (Pan
et al., 2002). Recently, a letter of reply to Kascak (2010)
answered by Zou et al., (2010a) gave general agreement
that 106KTNMK110 lacks Met112 (Zou et al., 2010b),
suggesting that these five residues constitute a minimal
3F4 epitope. Figure 7 further on shows the trace of the
putative epitope in our model.
(See figure 7 in: Yves Chapron*, Laurent Charlet and Nita Sahai. 2014, Fate of pathological prion (PrPsc92–138) in soil and water: prion-clay nanoparticle molecular Dynamics. Journal of Biomolecular Structure and Dynamics, Vol. 32, No. 11, 1802–1816)